Phase 2a Clinical Study Data of AJM300, an Oral α4 Integrin Antagonist, Will Be Presented in Digestive Disease Week 2014

Ajinomoto Pharmaceuticals Co., Ltd. (President, Takashi Nagamachi; Headquarters, Chuo-ku, Tokyo) today announced that the abstract of phase 2a clinical study data of an oral α4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 – 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.

<Study data to be presented>  (Presentation date/time: USA Eastern time zone)

<table>
<thead>
<tr>
<th>Abstract No.</th>
<th>Title</th>
<th>Presentation date/time</th>
</tr>
</thead>
<tbody>
<tr>
<td>370</td>
<td>AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo-Controlled* Phase 2A Study</td>
<td>May 4, 2014 1:36-1:46PM Oral presentation</td>
</tr>
</tbody>
</table>

*Randomized double-blind, placebo-controlled study

Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.

[Contact]

Corporate Planning Dept., Ajinomoto Pharmaceuticals Co., Ltd.
e-mail: contact_ajis@ajinomoto.com
TEL: +81-(0)3-6280-9802